A study to determine the maintenance of efficacy of agomelatine to prevent relapse in out-patients with major depressive disorder. A 8 to 10 weeks open period treatment with agomelatine followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period

Trial Profile

A study to determine the maintenance of efficacy of agomelatine to prevent relapse in out-patients with major depressive disorder. A 8 to 10 weeks open period treatment with agomelatine followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2014

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2009 Results published in the Journal of Clinical Psychiatry.
    • 03 Sep 2008 Endpoint 'Hamilton Depression Rating Scale' has been met. Results presented at ECNP
    • 19 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top